Publications by authors named "Annette Reichardt"

Claim this Profile
S
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial.
Heikki Joensuu, Annette Reichardt, Mikael Eriksson, Peter Hohenberger, Kjetil Boye, Peter Reichardt

Br J Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial.
Heikki Joensuu, Eva Wardelmann, Mikael Eriksson, Annette Reichardt, Kirsten Sundby Hall, Peter Reichardt

Clin Cancer Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study.
Anna Stoliaroff-Pepin, Caroline Peine, Tim Herath, Johannes Lachmann, Wiebke Hellenbrand, Annette Reichardt

Infection· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early myocardial oedema can predict subsequent cardiomyopathy in high-dose anthracycline therapy.
Fabian Muehlberg, Markus Kornfeld, Leonora Zange, Saeed Ghani, Annette Reichardt, Peter Reichardt

ESC Heart Fail· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022.
Anna Stoliaroff-Pepin, Caroline Peine, Tim Herath, Johannes Lachmann, Delphine Perriat, Annette Reichardt

Vaccine· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibrinogen-like protein 2 in gastrointestinal stromal tumour.
Olli-Pekka Pulkka, Leevi Viisanen, Olli Tynninen, Maria Laaksonen, Peter Reichardt, Annette Reichardt

J Cell Mol Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreased Incidence of Oncology Admissions in 75 Helios Hospitals in Germany during the COVID-19 Pandemic.
Peter Reichardt, Andreas Bollmann, Sven Hohenstein, Bertram Glass, Michael Untch, Annette Reichardt

Oncol Res Treat· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Barbara Hermes, Peter Reichardt

JAMA Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Heikki Joensuu, Eva Wardelmann, Harri Sihto, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Peter Reichardt

JAMA Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
Mikael Eriksson, Peter Reichardt, Kirsten Sundby Hall, Jochen Schütte, Silke Cameron, Annette Reichardt

Eur J Cancer· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Jörg T Hartmann, Peter Reichardt

J Clin Oncol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular targeted therapy of gastrointestinal stromal tumors.
Peter Reichardt, Annette Reichardt, Daniel Pink

Curr Cancer Drug Targets· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
George D Demetri, Paolo G Casali, Jean-Yves Blay, Margaret von Mehren, Jeffrey A Morgan, Annette Reichardt, Peter Reichardt

Clin Cancer Res· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis